Influence of drug therapy and adherence to it on the effectiveness of antiplatelet therapy in patients with chronic ischemic heart disease
Abstract
Background. Resistance to antiplatelet therapy increases the likelihood of cardiovascular complications and coronary death. Overcoming resistance to acetylsalicylic acid helps reduce the risk of developing cardiovascular events in the future.
Purpose. To evaluate the effectiveness of the enteric-coated form of acetylsalicylic acid in patients with chronic ischemic heart disease and to consider ways to overcome resistance to it.
Materials and methods. In order to assess the initial level of platelet aggregation activity, 74 patients were examined, 54 of whom formed the main group of patients with chronic coronary heart disease and 20 patients formed the control group.
Results. Initially, the level of platelet aggregation activity between the groups differed significantly. The differences persisted after the use of Thrombo ASS 100 mg/day, which suggested low efficiency of antiplatelet therapy in some patients. Combined use of acetylsalicylic acid and lipid-lowering therapy, along with high motivation of patients for drug treatment, led to an additional decrease in platelet aggregation activity and a decrease in resistance to it.
Conclusion. The results of the study indicate that patients with chronic coronary heart disease have significantly increased platelet aggregation activity. The use of lipid-lowering therapy and high adherence to drug treatment significantly increases the effectiveness of antiplatelet therapy.
EDN: IGOTOJ
Downloads
References
Агеев, Ф. Т., Смирнова, М. Д., & Фофанова, Т. В. (2023). Низкая приверженность терапии и пути её преодоления на примере антиагрегантной терапии. РМЖ. Медицинское обозрение, 7(1), 56–61. https://doi.org/10.32364/2587-6821-2023-7-1-56-61. EDN: https://elibrary.ru/MWYDWS
Барбараш, О. Л., Карпов, Ю. А., Панов, А. В., и др. (2024). Стабильная ишемическая болезнь сердца. Клинические рекомендации 2024. Российский кардиологический журнал, 29(9), 167–229. https://doi.org/10.15829/1560-4071-2024-6110. EDN: https://elibrary.ru/HHJJUT
Бурячковская, Л. И., Ломакин, Н. В., Русанова, А. В., и др. (2016). Резистентность к ацетилсалициловой кислоте: причины и следствие. Сердце: журнал для практикующих врачей, 15(5), 379–388. https://doi.org/10.18087/RHJ.2016.5.2261. EDN: https://elibrary.ru/WVNEPT
Росстат. (2023). Здравоохранение в России: статистический сборник. М.: Росстат, 179 с. https://rosstat.gov.ru/storage/mediabank/Zdravoohran-2023.pdf
Ломакин, Н. В., Сумароков, А. Б., Доценко, Ю. В., и др. (2017). Индивидуальный подход к применению антитромбоцитарной терапии. На что опереться в решении? Атеротромбоз, (2), 70–78. https://doi.org/10.21518/2307-1109-2017-2-70-78. EDN: https://elibrary.ru/XHLJGF
Лукина, Ю. В., Марцевич, С. Ю., & Кутишенко, Н. П. (2016). Шкала Мориски Грина: плюсы и минусы универсального теста, работа над ошибками. Рациональная фармакотерапия в кардиологии, 12(1), 63–65. https://doi.org/10.20996/1819-6446-2016-12-1-63-65. EDN: https://elibrary.ru/VRCVIZ
Лукина, Ю. В., Кутишенко, Н. П., Марцевич, С. Ю., и др. (2020). Опросники и шкалы для оценки приверженности к лечению — преимущества и недостатки диагностического метода в научных исследованиях и реальной клинической практике. Кардиоваскулярная терапия и профилактика, 19(3), 232–239. https://doi.org/10.15829/1728-8800-2020-2562. EDN: https://elibrary.ru/RIYCQR
Осокина, А. К., Щинова, А. М., Потехина, А. В., и др. (2021). Оценка приверженности к основным прогнозмодифицирующим препаратам и контроль факторов риска ишемической болезни сердца у больных, перенёсших коронарное стентирование. Медико социальная экспертиза и реабилитация, 24(4), 13–23. https://doi.org/10.17816/MSER107293. EDN: https://elibrary.ru/WCRWJL
Погосова, Н. В., Бойцов, С. А., Аушева, А. К., и др. (2021). Медикаментозная терапия и приверженность к ней пациентов с ишемической болезнью сердца: результаты российской части международного многоцентрового исследования EUROASPIRE V. Кардиология, 61(8), 4–13. https://doi.org/10.18087/cardio.2021.8.n1650. EDN: https://elibrary.ru/BMKKSC
Рузов, В. И., Комарова, Л. Г., Комаров, А. С., и др. (2020). Активность цитокиновой регуляции воспаления и эффект моно и двойной антиагрегантной терапии у пациентов с ишемической болезнью сердца и синдромом обструктивного апноэ сна. Кардиоваскулярная терапия и профилактика, 19(2), 49–54. https://doi.org/10.15829/1728-8800-2020-2261. EDN: https://elibrary.ru/TAFCZY
Фролова, Н. С., Шахнович, Р. М., Казначеева, Е. М., и др. (2010). Резистентность к аспирину у больных с острым коронарным синдромом. Часть 1. Кардиоваскулярная терапия и профилактика, 9(6), 40–46. EDN: https://elibrary.ru/MUPPCP
Фролова, Н. С., Шахнович, Р. М., Казначеева, Е. М., и др. (2011). Резистентность к аспирину у больных с острым коронарным синдромом. Часть 2. Кардиоваскулярная терапия и профилактика, 10(2), 47–52. https://doi.org/10.15829/1728-8800-2011-2-47-52. EDN: https://elibrary.ru/NHMIPJ
Хакимова, М. Б., Комаров, А. Л., Добровольский, А. Б., и др. (2022). Персонификация антиагрегантной терапии у больных с ишемической болезнью сердца: прошлое, настоящее и будущее. Кардиологический вестник, 17(4), 5–15. https://doi.org/10.17116/Cardiobulletin2022170415. EDN: https://elibrary.ru/WQLCOA
Albert, M. A., et al. (2001). Effect of statin therapy on C reactive protein levels. The pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA, 286(1), 64–70. https://doi.org/10.1001/jama.286.1.64
Baigent, C., Blackwell, L., Collins, R., et al. (2009). Aspirin in the primary and secondary prevention of vascular disease: collaborative meta analysis of individual participant data from randomized trials. The Lancet, 373, 1849–1860. https://doi.org/10.1016/S0140-6736(09)60503-1
Born, G. V. (1962). Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature, 9, 927–929. https://doi.org/10.1038/194927b0
Eikelboom, J. W. (2003). Aspirin resistance: a new independent predictor of vascular events? Journal of the American College of Cardiology, 41(6), 966–968. https://doi.org/10.1016/s0735-1097(02)03013-9. EDN: https://elibrary.ru/BGBNCV
Eriksen, C. U., Rotar, O., Toft, U., & Jørgensen, T. (2021). WHO Health Evidence Network synthesis report (p. 8). Copenhagen. ISBN: 978 92 890 5537 6
Krasopoulos, G., et al. (2008). Aspirin “resistance” and risk of cardiovascular morbidity: systematic review and meta analysis. BMJ, 336, 195–198. https://doi.org/10.1136/bmj.39430.529549.BE
Levin, R. I. (2005). The puzzle of aspirin and sex. New England Journal of Medicine, 352(13), 1293–1304. https://doi.org/10.1056/NEJMe058051
Mason, P. J., et al. (2005). Aspirin resistance and atherothrombotic disease. Journal of the American College of Cardiology, 46(6), 986–993. https://doi.org/10.1016/j.jacc.2004.08.070
Masoudi, F. A., et al. (2005). Aspirin use in older patients with heart failure and coronary artery disease. Journal of the American College of Cardiology, 46(6), 955–962. https://doi.org/10.1016/j.jacc.2004.07.062
Nardin, M., Verdoia, M., Cao, D., et al. (2023). Platelets and the atherosclerotic process: an overview of new markers of platelet activation and reactivity, and their implications in primary and secondary prevention. Journal of Clinical Medicine, 12(18), 6074. https://doi.org/10.3390/jcm12186074. EDN: https://elibrary.ru/CUZYFL
Ridker, P. M., et al. (2005). A randomized trial of low dose aspirin in the primary prevention of cardiovascular disease in women. New England Journal of Medicine, 352(13), 1293–1304. https://doi.org/10.1056/NEJMoa050613
Zeng, W., Chu, T. T. W., Chow, E. Y. K., et al. (2022). Factors associated with aspirin resistance in Hong Kong Chinese patients with stable coronary heart disease using the Multiplate® analyzer and serum thromboxane B2. Pharmaceutics, 14(10), 2099. https://doi.org/10.3390/pharmaceutics14102099. EDN: https://elibrary.ru/VXEJXE
References
Ageev, F. T., Smirnova, M. D., & Fofanova, T. V. (2023). Low adherence to therapy and ways to overcome it: the case of antiplatelet therapy. RMJ. Medical Review, 7(1), 56–61. https://doi.org/10.32364/2587 6821 2023 7 1 56 61. EDN: https://elibrary.ru/MWYDWS
Barbarash, O. L., Karpov, Yu. A., Panov, A. V., et al. (2024). Stable ischemic heart disease. Clinical guidelines 2024. Russian Journal of Cardiology, 29(9), 167–229. https://doi.org/10.15829/1560 4071 2024 6110. EDN: https://elibrary.ru/HHJJUT
Buryachkovskaya, L. I., Lomakin, N. V., Rusanova, A. V., et al. (2016). Resistance to acetylsalicylic acid: causes and consequences. Heart: Journal for Practicing Physicians, 15(5), 379–388. https://doi.org/10.18087/RHJ.2016.5.2261. EDN: https://elibrary.ru/WVNEPT
Rosstat. (2Newton). Healthcare in Russia: Statistical Compendium. Moscow: Rosstat. 179 pp. Retrieved from: https://rosstat.gov.ru/storage/mediabank/Zdravoohran-2023.pdf
Lomakin, N. V., Sumarokov, A. B., Dotsenko, Yu. V., et al. (2017). Individualized approach to antiplatelet therapy: what to rely on in decision making? Atherothrombosis, (2), 70–78. https://doi.org/10.21518/2307 1109 2017 2 70 78. EDN: https://elibrary.ru/XHLJGF
Lukina, Yu. V., Martsevich, S. Yu., & Kutishenko, N. P. (2016). The Morisky Green scale: pros and cons of the universal test, correcting mistakes. Rational Pharmacotherapy in Cardiology, 12(1), 63–65. https://doi.org/10.20996/1819 6446 2016 12 1 63 65. EDN: https://elibrary.ru/VRCVIZ
Lukina, Yu. V., Kutishenko, N. P., Martsevich, S. Yu., et al. (2020). Questionnaires and scales for assessing treatment adherence — advantages and disadvantages of the diagnostic method in research and real clinical practice. Cardiovascular Therapy and Prevention, 19(3), 232–239. https://doi.org/10.15829/1728 8800 2020 2562. EDN: https://elibrary.ru/RIYCQR
Osokina, A. K., Shchinova, A. M., Potekhina, A. V., et al. (2021). Assessment of adherence to key prognosis modifying medications and risk factor control in coronary heart disease patients after coronary stenting. Medical and Social Expertise and Rehabilitation, 24(4), 13–23. https://doi.org/10.17816/MSER107293. EDN: https://elibrary.ru/WCRWJL
Pogosova, N. V., Boytsov, S. A., Ausheva, A. K., et al. (2021). Drug therapy and adherence in patients with coronary heart disease: results of the Russian part of the international multicenter study EUROASPIRE V. Kardiologiia, 61(8), 4–13. https://doi.org/10.18087/cardio.2021.8.n1650. EDN: https://elibrary.ru/BMKKSC
Ruzov, V. I., Komarova, L. G., Komarov, A. S., et al. (2020). Cytokine regulation of inflammation activity and the effect of mono and dual Antiplatelet therapy in patients with coronary heart disease and obstructive sleep apnea syndrome. Cardiovascular Therapy and Prevention, 19(2), 49–54. https://doi.org/10.15829/1728 8800 2020 2261. EDN: https://elibrary.ru/TAFCZY
Frolova, N. S., Shakhnovich, R. M., Kaznacheeva, E. M., et al. (2010). Aspirin resistance in patients with acute coronary syndrome. Part 1. Cardiovascular Therapy and Prevention, 9(6), 40–46. EDN: https://elibrary.ru/MUPPCP
Frolova, N. S., Shakhnovich, R. M., Kaznacheeva, E. M., et al. (2011). Aspirin resistance in patients with acute coronary syndrome. Part 2. Cardiovascular Therapy and Prevention, 10(2), 47–52. https://doi.org/10.15829/1728 8800 2011 2 47 52. EDN: https://elibrary.ru/NHMIPJ
Khakimova, M. B., Komarov, A. L., Dobrovolsky, A. B., et al. (2022). Personalization of Antiplatelet therapy in patients with coronary heart disease: past, present, and future. Cardiological Bulletin, 17(4), 5–15. https://doi.org/10.17116/Cardiobulletin2022170415. EDN: https://elibrary.ru/WQLCOA
Albert, M. A., et al. (2001). Effect of statin therapy on C reactive protein levels. The pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA, 286(1), 64–70. https://doi.org/10.1001/jama.286.1.64
Baigent, C., Blackwell, L., Collins, R., et al. (2009). Aspirin in the primary and secondary prevention of vascular disease: collaborative meta analysis of individual participant data from randomized trials. The Lancet, 373, 1849–1860. https://doi.org/10.1016/S0140-6736(09)60503-1
Born, G. V. (1962). Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature, 9, 927–929. https://doi.org/10.1038/194927b0
Eikelboom, J. W. (2003). Aspirin resistance: a new independent predictor of vascular events? Journal of the American College of Cardiology, 41(6), 966–968. https://doi.org/10.1016/s0735-1097(02)03013-9. EDN: https://elibrary.ru/BGBNCV
Eriksen, C. U., Rotar, O., Toft, U., & Jørgensen, T. (2021). WHO Health Evidence Network synthesis report (p. 8). Copenhagen. ISBN: 978 92 890 5537 6
Krasopoulos, G., et al. (2008). Aspirin “resistance” and risk of cardiovascular morbidity: systematic review and meta analysis. BMJ, 336, 195–198. https://doi.org/10.1136/bmj.39430.529549.BE
Levin, R. I. (2005). The puzzle of aspirin and sex. New England Journal of Medicine, 352(13), 1293–1304. https://doi.org/10.1056/NEJMe058051
Mason, P. J., et al. (2005). Aspirin resistance and atherothrombotic disease. Journal of the American College of Cardiology, 46(6), 986–993. https://doi.org/10.1016/j.jacc.2004.08.070
Masoudi, F. A., et al. (2005). Aspirin use in older patients with heart failure and coronary artery disease. Journal of the American College of Cardiology, 46(6), 955–962. https://doi.org/10.1016/j.jacc.2004.07.062
Nardin, M., Verdoia, M., Cao, D., et al. (2023). Platelets and the atherosclerotic process: an overview of new markers of platelet activation and reactivity, and their implications in primary and secondary prevention. Journal of Clinical Medicine, 12(18), 6074. https://doi.org/10.3390/jcm12186074. EDN: https://elibrary.ru/CUZYFL
Ridker, P. M., et al. (2005). A randomized trial of low dose aspirin in the primary prevention of cardiovascular disease in women. New England Journal of Medicine, 352(13), 1293–1304. https://doi.org/10.1056/NEJMoa050613
Zeng, W., Chu, T. T. W., Chow, E. Y. K., et al. (2022). Factors associated with aspirin resistance in Hong Kong Chinese patients with stable coronary heart disease using the Multiplate® analyzer and serum thromboxane B2. Pharmaceutics, 14(10), 2099. https://doi.org/10.3390/pharmaceutics14102099. EDN: https://elibrary.ru/VXEJXE
Copyright (c) 2025 Oksana V. Demyanenko, Valery I. Vishnevsky, Irina A. Snimshchikova, Maria O. Revyakina
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
